ninth Diabetes for mid-single-digit PFA quarter We had quarter in Ablation us single pipeline areas, Neuromodulation, by Hello strong We delivered Heart, Cardiac in Cranial high largest advanced Structural joining grew excluding our several digits. grew & growth double growth in Congenital, are performances U.S. portfolio. everyone, Denervation. We Technologies total and row. Spinal And opening up today. both revenue powered med XX% another innovation in and with the Solutions, and market and addressable of thanks tech for pacing, with a the Leadless starting Renal all our digits.
in of stacking growth with drivers And our markets EPS end It's and and to EPS attractive most an gross margin. markets dynamic momentum growth on to with in We with power fourth exciting growth we overcame high the strong our and a U.S. of and operating build short-term both earnings we guidance quarter, ahead drive growth margin accelerate, expect continue in we the fiscal as look of top and time med improvements our on important range in innovation of ahead single-digit to leverage. growth both as strong our consensus revenue we're as high tech. some drivers groundbreaking in earnings delivered coming distributor
durable shareholders. our revenue value significant and formula to flow our growth, delivering cash expect create earnings We free strong for of generating leveraged
was grew and discuss details Solutions Starting our mid-single turn our business which let's Now Ablation our to of QX Cardiovascular overall. business. with Cardiac digits the results portfolio, first our highlight performance. The
quarter XX%. double-digit meaningful growth delivered strong acceleration, this CAS forecasted and we Now growing
for on to products field hit portfolio are Our and new a accelerate. continues demand PFA We've our supply pulsed growth. rapid ablation driving gear
only gives the are company with PFA which platforms, X flexibility. us Affera We and PulseSelect,
we increasing integrated high-density well and focal in mapping workhorse case our with pack RF its and the as This as catheters. both as desired platform is catheter. capabilities the Affera has RF competitors' separated itself as replace a revenue PF mapping per from most
We PulseSelect compete. they catheter, globally a and us want have use to ton as just customers it more. PulseSelect. more market PFA grow also gives and the single-shot this of use And flexibility to
Affera use, factors increasingly, their significant PulseSelect ease profile precision, platforms, our technology their We and our is our outlook. the in us customers is now, efficacy of Across gives of high appreciate it one durable profile. believe competitively, differentiation confidence of PFA and differentiated both of point safety a safety several and that
expect rapid we growth this ahead, to looking trajectory continue. Now
growth we strong business its have new This billion another double-digit For quarter. portfolio the fiscal billion around expect rate to year, us of sight as and growth and PFA line a $X world. our $X CAS QX, we to into will accounts accelerate be for deliver this expands
congenital. Heart, Structural excluding high grew in we digits, single Next,
to see continue U.S. TAVR a Evolut system and very off launch the our good international the in FX+ start. adoption We is to of good
we we as catalysts, we Evolut As ahead, some evidence look to upcoming on have our continue data platform. the long-term benefits of important share
a improvements, and we've by presented execution X-year the will data strong at at and largest trial, be clinical be ACC our later business. really team, from it's SMART low-risk versus month important next data we're moment really this head-to-head our now spot. is competitor, will in a data, Look, shared which a late-breaker X-year as TAVR where spring. good now Our solidified this With a product
XX% QX, pacemaker continue. delivering anniversary this strength now leadless expect growth XXth for technology. to the pacemaker receiving grew on our continues we our now pacing we This And Next, row Micra single decade upper mark business the system of in and strength CE Mark. grown In a later, first franchise digits and standard, the April, we franchise Micra in in a quarters conduction will set our cardiac XX X%. pacing of has outstanding therapies, to leadless
Symplicity is pressure. and Medicare just for hypertension months. as month, pivotal news place is We're and helping we the new exciting U.S. care clinics analysis. Medicare set our last them activating change establish when CMS and a we will the opened accounts across to X poised blood care to This And now of turning the and pressure in a coverage up procedure. pathways. Symplicity Now in blood uncontrolled next place. payment now have development coding had high We're standard national coverage within
So of upon a to they're coverage, And coverage an for growth will be become growth source immediate is significant when this will procedures ramp in the quickly and prepared driver place. company.
half numerous have Nearly of those they despite X have the medications. don't of of under U.S. broad hypertension in and just control X adults with availability hypertension, generic it
can the together, be this And here expect and and to is back, the So And portfolio, to addressing at population the in take massive, these working. in unmet standard leader overall we're of The cardiovascular poised accelerate meaningfully need. step care current the want growth health Physicians is systems we growth do look the ahead, just just opportunity drivers large as Patients as all a of procedure. starting therapy. it. quarters QX. The its large. easily support new this isn't we taking with patient we
mid-single the Turning another to our Cranial won X% we portfolio, Technologies, quarter which quarter. U.S., Spinal digits grew point X% with strong had this neuroscience as global also another share. & growth in we of including In growth,
when causing major And time in the you now I've saying month competition a of decided that changing. robotics, technology. the recently market competitor AI-driven including disruption post-op example and get causing We're instruments. of pre-op basis our last this spine to Siemens rapidly with imaging, powered enabling of And our is into Healthineers. pre- imaging arsenal differentiated disruption. navigation software, and with through expanded planning this surgical we partnership saw Now business. for yet We're out another the been some Spine
full Look, of to struggle certain pieces, them just complement those exit company surgeons market have make competitors innovative the offer choice, And them technologies. or the they're and well, altogether. seeing or that only can't this standardizing a with we're can that can either offer
attracting continue above-market differentiated spine as is best-in-class as we the distributors to as best play expand to growth. innovation we these and continue surgeons competitors. business the and sustained deliver Our out, well AiBLE our dynamics expect our ecosystem lead, from And CST to reps best
XX%, can the well The a competitive we've technology modulation and the feat. execution both Next, above system. compete, sensing which just dynamics. innovation to which patients commercial on Spine, the closed-loop in better therapies load big developed health in is engineering market. is brain and lessen it for Neuromodulation now and stim evident And And be scale, strong it care raises growth. that Neuromod has takes personalized what disrupting at our grew pain game-changing We for like that is the the been can have our on bar
pain. XX%, XX% of instantly device, the grew the and on And dose. on our the best adjusts feature keep with very Inceptiv conditional including in the for Stim, On Pain top at the cord spinal Inceptiv U.S., SCS the access thinnest a market, MRI therapy stimulator. optimal neural full responses smallest which we closed-loop strength to patients chronic on it being based important In body has is of an
In With Last Brain grew and XX% for treatment month, technology, through tremor, Adaptive in therapy systems. we systems feedback. with real-time fully personalized, XX%, with by the disorders DBS the its of like Percept Parkinson's, Modulation, brain is adoption our transforming and driven interface we epilepsy. essential patients Percept U.S., technology computer including movement dystonia brain Percept this BrainSense activity a upgrade, automatic our devices, adjustments received CE DBS on software closed-loop based groundbreaking become Mark for with can people clearance Parkinson's. for
quarters above-market launch for growth Brain this ahead. business continued Now the we expect our to in drive Mod
Now our Surgical Medical to turning portfolio.
Let's Surgical. discuss performance our in
we hundred Surgical experienced impact a quarter, buying of in patterns, on distributor which a basis performance. This had point couple change our U.S.
purchasing and franchise, Energy us high stable. and by this pressures markets. we by as We distributor expect start strong resolve from and market 'XX. continue in to our see competitive this U.S. products globally has from customer this emerging to growth fiscal through stapling winning direct Apart our offsetting And share with we're dynamic, driving while distributors hospital we single-digit been our LigaSure/Advanced in
system the platform, In I indications soft adding some with than Hugo important by U.S., Hugo U.S. indications, performance. have new also including submit you our track continues to to we've we next for on are market, today. With the and features procedure milestones, approval the volume utilization tissue FDA information with enhancing to some expanding share month. year-over-year. doubled of Hugo end international entering more for increase, we're and markets, robotic In approaching urology
our GYN Hernia actively enrollment We and IDE recently have Further, finished moving oncology forward. study to and are we approval initiate that benign received in FDA GYN our studies.
progress features our making cases to technology expect to also and completed calendar our and LigaSure year. sealing vessel imaging, our ICG we add this adding fluorescent just instrumentation. first using later We We're Hugo
our driver the midterm. we in meaningful for Hugo forward. our confident be growth and So business Medtronic 'XX in in surgical will in path a are fiscal a for total, growth driver
growth XX% in quarter Diabetes, We prior growth. in our in printed we year. double-digit had XX% the of of Finally, row on growth fifth a top
driven Our within by: category. of to overall is growth XXXG AID stand-alone two, systems; market move strength CGM of with MDI our the from AID the system one, the and MiniMed the
to continue in seeing XXXG base, well and high we're very consumables. our CGM grow growth attachment strong installed rates as We as
the user make half the Simplera apply easier In the Europe, Sync sensor, sensor. on size approval, we've the excellent work our we're is we're Sync and to which previous FDA Abbott-based In much getting sensor. for continuing integration U.S., submitted with progress our on feedback Simplera and than also to
these accelerate our expect when really X new fully We U.S. to sensors growth launched.
pumps, diabetes, for in meaningful expanded a our algorithms. robust including also X including pipeline, pumps, labeling which and opportunity. diabetes next-gen we're smart sensors, the type seeking new pens durable XXXG, investing also heavily is technology We're Beyond patch
the to the in calendar expect of with here the year. this half first We file FDA
disciplined we leveraged continue our into you're and SG&A benefits holding We're growth, now realizing our including scale, growth pricing, earnings sales, as translate this doubling power. Medtronic, delivering mid-single-digit across our COGS and productivity. we to strong more earnings than on focus drive underlying the of So below seeing
our through and you Gary at Gary, financial performance walk will our outlook. you. look QX over now a to deeper
